Edaravone for new anti-AQP4 optic neuritis
Part of Brain & nervous system, Eyes & vision clinical trials.
This trial tests edaravone, a medicine intended to reduce damage from optic neuritis, in adults whose condition is confirmed by a positive blood test for anti-AQP4 antibodies. It may help people who are in the first month after their first episode to preserve or improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and able to join as a Chinese patient
- Your optic neuritis is confirmed by a positive anti-AQP4 antibody test
- This is your first episode of optic neuritis (in either eye)
- Your first symptoms started 30 days or less before the first edaravone dose
- You do not have severe nearsightedness (myopia worse than 6 diopters)
- Eye media clarity is good enough for doctors to measure retinal layers and your vision accurately
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called efgartigimod for people having their first episode of optic neuritis (inflammation of the optic nerve). The goal is to see if it can help protect your vision better than standard treatment alone.
This study tests whether a new experimental medicine called CC-97540 is safe and well-tolerated in patients with a rare neurological disease called neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody marker (anti-AQP4). The trial involves a procedure that removes and reprocesses some of your immune cells.
This trial tests a new drug called ANXV (Annexin A5) to see if it is safe and can help people with diabetic retinopathy or a recent retinal vein occlusion. The goal is to reduce eye damage and improve vision.
This study tests if ravulizumab can lower certain nerve damage markers in people with AQP4-positive neuromyelitis optica. It may help understand how well the treatment works.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
Hear when a new Optic Neuritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.